May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Treatment of Retinal Angiomatous Proliferation with Pan-VEGF A Inhibition
Author Affiliations & Notes
  • C. T. Cessna
    Department of Ophthalmology & Vision Science, UC Davis Medical Center, Sacramento, California
  • S. N. Truong
    Department of Ophthalmology & Vision Science, UC Davis Medical Center, Sacramento, California
  • D. G. Telander
    Department of Ophthalmology & Vision Science, UC Davis Medical Center, Sacramento, California
  • S. S. Park
    Department of Ophthalmology & Vision Science, UC Davis Medical Center, Sacramento, California
  • L. S. Morse
    Department of Ophthalmology & Vision Science, UC Davis Medical Center, Sacramento, California
  • Footnotes
    Commercial Relationships C.T. Cessna, None; S.N. Truong, None; D.G. Telander, None; S.S. Park, None; L.S. Morse, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3372. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. T. Cessna, S. N. Truong, D. G. Telander, S. S. Park, L. S. Morse; Treatment of Retinal Angiomatous Proliferation with Pan-VEGF A Inhibition. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3372.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy of pan-VEGF A inhibition with either intravitreal bevacizumab or ranibizumab in the treatment of retinal angiomatous proliferation (RAP), a form of neovascular age-related macular degeneration.

Methods:: Four patients with primary or recurrent RAP lesions diagnosed by fluorescein angiography and high-resolution Fourier-domain Optical Coherence Tomography (OCT) underwent intravitreal injection(s) of either bevacizumab 1.25mg or ranibizumab 0.5mg. Treatment was repeated if persistent cystoid macular edema or subretinal fluid was noted on Stratus OCT at monthly follow-up examinations. Two patients had newly diagnosed RAP lesions and two had recurrent RAP lesions that had been treated with photodynamic therapy and intravitreal kenalog at least 6 months earlier.

Results:: All patients showed an anatomical improvement on Stratus OCT and an improvement in BCVA with pan-VEGF A inhibition. At a mean follow-up of 3.5 months (range 2 to 6 months)(will have a range of 4 to 8 months with a 5.5 month mean follow-up), the mean BCVA improved from a baseline of 20/120 (logMar 0.8) to 20/60 (logMar 0.45) giving an average 3.5 line gain after an average of 2.25 intravitreal injections (range 1 to 4) of either bevacizumab or ranibizumab.

Conclusions:: Various treatment modalities for RAP lesions secondary to AMD have been reported in the literature with variable results. Pan-VEGF A inhibition appears to be an effective treatment option for patients with primary or recurrent RAP lesions secondary to AMD even after failure with other treatment modalities.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×